Company Info
| Industry | Pharmaceuticals: Major |
|---|---|
| Sector | Health Technology |
| Employees | 30,250 |
| CEO | Dr. Giovanni Caforio |
| Address | 430 East 29th Street 14th floor, New York, NY 10016 |
|---|---|
| Phone | 1.212.546.4000 |
| Website | www.bms.com |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Bristol Myers Squibb Co. | -16.50% | -11.95% |
| Thermo Fisher Scientific, Inc. | 11.47% | 32.91% |
| Novo Nordisk A/S | 6.42% | 58.91% |
| Eli Lilly & Co. | -3.21% | 71.15% |
| Danaher Corp. | -2.41% | 42.10% |
Statement Summary
as of 4:10 ET PM 11/30/2021| Total Assets (MRQ) | 110.9 B |
|---|---|
| Total Liabilities (MRQ) | 73.6 B |
| Shareholders’ Equity (MRQ) | 37.3 B |
| Total Revenue (Annual) | 11.6 B |
| Net Income (Annual) | 1.5 B |
Earnings And Estimates
as of 4:10 ET PM 11/30/2021
| Current Qtr EPS Estimate | 1.82 |
|---|---|
| Current FY EPS Estimate | 7.50 |
| Long Term EPS Growth Estimate | 5.20 |
| Next Expected Earnings Date | 2/4/2022 |
BMY vs S&P 500
as of 11/30/2021| Relative To S&P 500 |
BMY | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:10 ET PM 11/30/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 09/2021 | 1.92 | 2.00 | +4.24% |
| 06/2021 | 1.89 | 1.93 | +2.32% |
| 03/2021 | 1.81 | 1.74 | -3.61% |
| 12/2020 | 1.42 | 1.46 | +3.13% |
| 09/2020 | 1.49 | 1.63 | +9.40% |
| 06/2020 | 1.48 | 1.63 | +9.85% |
| 03/2020 | 1.49 | 1.72 | +15.73% |
| 12/2019 | 0.88 | 1.22 | +38.17% |
Financial Strength
as of 4:10 ET PM 11/30/2021| Pre-Tax Margin | 18.56 |
|---|---|
| Net Margin | -25.12 |
| Operating Margin | 14.90 |
| Return On Equity | -12.37 |
| Return On Assets | -4.57 |
| Inventory Turnover (TTM) | 9.56 |
| Sales Growth (MRQ) | 20.75 |
Ratios
as of 4:10 PM ET 11/30/2021| Price/Earnings (TTM) | n/a |
|---|---|
| Price/Book (MRQ) | 3.28 |
| Price/Cash Flow (TTM) | 7.79 |
| Book Value (MRQ) | 16.77 |
| Quick Ratio (MRQ) | 1.36 |
| Current Ratio (MRQ) | 1.47 |
| Total Debt/Equity (MRQ) | 1.23 |
Short Interest
as of 4:10 PM ET 12/01/2021| % Short - 0.92% | |
| % Remaining Float - 99.08% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | 11/15/2021 | 10/29/2021 |
| Short Interest Shares | 20,256,733 | 22,398,028 |
| Short Interest Ratio | 1.9 | 1.9 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:10 ET PM 11/30/2021| Current Qtr (12/2021) |
Next Qtr (03/2022) |
|
|---|---|---|
| Consensus Estimate | $1.82 | $2.04 |
| # of Estimates | 14 | 5 |
| High Estimate | $1.88 | $2.23 |
| Low Estimate | $1.74 | $1.82 |
| Year Ago EPS | $-4.45 | $0.90 |
| Year Over Year Growth Estimate | -140.98% | 125.60% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $7.50 | $7.87 |
| # of Estimates | 18 | 18 |
| High Estimate | $7.58 | $8.07 |
| Low Estimate | $7.35 | $7.46 |
| Year Ago EPS | $6.44 | $7.50 |
| Year Over Year Growth Estimate | 16.43% | 4.92% |
| Current Qtr (12/2021) |
Next Qtr (03/2022) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $1.82 | $2.04 | $7.50 | $7.87 |
| # of Estimates | 14 | 5 | 18 | 18 |
| High Estimate | $1.88 | $2.23 | $7.58 | $8.07 |
| Low Estimate | $1.74 | $1.82 | $7.35 | $7.46 |
| Year Ago EPS | $-4.45 | $0.90 | $6.44 | $7.50 |
| Year Over Year Growth Estimate | -140.98% | 125.60% | 16.43% | 4.92% |
Insider Information Summary
as of 11/30/2021| % Insiders - 0.27% | |
| % Remaining Total Shares - 99.73% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | -76.13 K | -139.59 K |
| Shares Bought | 0.00 | 382.04 K |
| Shares Sold | 76.13 K | 521.63 K |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Learn to Trade Like a Pro
Master The Market with the Help of Our Financial Experts
LATEST NEWS
Latest News
Bristol Myers Stock Falls Despite Positive News on Psoriasis Drug
Nov 29, 2021 10:17 AM EST
AbbVie Stock Rises on Upgrade to Buy from Hold by SocGen
Nov 23, 2021 12:32 PM EST
Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review
Nov 19, 2021 2:02 PM EST
Stocks Edge Lower; Microsoft Earnings Leap, Billionaires' Tax Plan - 5 Things You Must Know
Oct 27, 2021 11:13 AM EDT
Earnings Recap: Boeing, McDonald’s, GM, Coca-Cola, Spotify
Oct 27, 2021 8:17 AM EDT
Bristol Meyers Squibb Posts Earnings Beat and Lifts Guidance
Oct 27, 2021 7:57 AM EDT
Cramer's Mad Money Recap 10/13: FedEx, J.B. Hunt, Costco, Starbucks
Oct 13, 2021 7:17 PM EDT
The Case for a Bounce in Bristol-Myers Squibb
Oct 4, 2021 12:00 PM EDT
Amicus Therapeutics Stock Rises; Sells Unit Stake in SPAC Deal
Sep 30, 2021 10:24 AM EDT
Acceleron Pharma Stock Climbs on Reported $11B Deal Talks
Sep 27, 2021 9:56 AM EDT
Cramer's Mad Money Recap: Advanced Micro Devices, Nvidia, Thor
Sep 24, 2021 6:42 PM EDT
Stock Market Today With Jim Cramer: How to Trade Ford
Sep 17, 2021 5:03 PM EDT
Markets Fell Faster Than Expected, Cramer Says - Here's When He Would Begin Buying
Sep 17, 2021 12:32 PM EDT
Drug Stocks Drop on White House Plan to Lower Drug Costs
Sep 9, 2021 11:59 AM EDT
Cramer's Mad Money Recap: Amazon, CVS, Walmart
Aug 24, 2021 7:30 PM EDT
Cramer's Mad Money Recap: Home Depot, Ford, Disney
Aug 18, 2021 7:15 PM EDT
Jim Cramer Eyes a 'Remultiplization' of the Drug Stocks
Aug 18, 2021 1:53 PM EDT
5 Top Stock Gainers for Tuesday: 23andMe, Kroger, Monday.com
Aug 17, 2021 12:52 PM EDT
Warren Buffett's Berkshire Hathaway Cuts Stake in General Motors, Boosts Kroger Holdings
Aug 17, 2021 6:25 AM EDT
Home Depot Pushes Dow Futures Lower on Growth Concern; Retail Sales Disappoint
Aug 17, 2021 5:49 AM EDT
Walmart, Home Depot, GM, Roblox, Jerome Powell: 5 Things You Must Know
Aug 17, 2021 5:04 AM EDT
BeyondSpring Stock Doubles After Report of Cancer-Drug Progress
Aug 4, 2021 9:45 AM EDT
Video: Jim Cramer on Boeing, Facebook, Alphabet, AMD, Starbucks, the CDC
Jul 28, 2021 9:48 AM EDT
Bristol Myers Posts Stronger-Than-Expected Earnings but Lowers Guidance
Jul 28, 2021 8:47 AM EDT
Recent Articles from TheStreet
Glaxo-Vir Antibody Drug Appears Effective vs. Omicron, Cleared by UK
GlaxoSmithKline says its antibody drug was 'deliberately designed with a mutating virus in mind.'
MLB Locks Out Players as New TV Deals Set to Start in 2022
Major League Baseball locks out players for first time in a quarter century after the league and players association fail to strike a collective bargaining deal.
Trump Venture Seeks $1B Hedge-Fund Backing for Social-Media Plan
Trump Media & Technology is valued at $875 million. It is seeking to raise $1 billion at a valuation close to $3 billion, a media report says.
Hulbert: The Santa Claus Rally Isn't Real; Don't Buy Into It
Is Wall Street shamelessly trying to get you to invest in the market over the holidays? History indicates there's really no proof of a so-called 'Santa Claus Rally.'
Plug Power, Exxon Mobil Touted by Wells Fargo on Spending Bill
Wells Fargo put together a list of stocks that should benefit if the Senate joins the House in approving the Build Back Better bill.
One in 10 American Consumers Hurt by Inflation: Gallup
Gallup finds that one in every 10 consumers in America is dealing with severe money worries due to rising costs for goods and services.
Premarket Movers Thursday - Apple, Boeing, Uber
Some of the top movers ahead of Thursday's trading session are Boeing, Uber and Snowflake.
Ford Stock Downgraded to Peer Perform by Wolfe Research
Ford's stock price now reflects the upside, according to Wolfe Research, which also raised its one-year price target to $22 from $17.
Dollar General Accelerates Adoption of Higher-End Popshelf Store Concept
Dollar General is accelerating the adoption of its Popshelf store concept targeting wealthy, suburban shoppers, with plans for 1,000 stores by fiscal 2025.
China Challenge: Persuading Citizens to Use the Digital Yuan
It turns out the Chinese government has some work to do just to get its own citizens on board for the e-CNY, a media report says.